LTK and non-small cell lung carcinoma: However, despite the remarkable efficacy of lorlatinib against NSCLC patients harboring CLIP1-LTK, acquired resistance to lorlatinib will inevitably develop, as observed in NSCLC induced by oncogenic tyrosine kinases treated with corresponding TKIs7–11.